Cas:883555-10-0 tert-butyl N-[4-fluoro-2-(1-hydroxyethyl)phenyl]carbamate manufacturer & supplier

Chemical Name:tert-butyl N-[4-fluoro-2-(1-hydroxyethyl)phenyl]carbamate

CAS.NO:883555-10-0

Synonyms:tert-Butyl 4-fluoro-2-(1-hydroxyethyl)phenylcarbamate;PC9587;(tert-butoxy)-N-[4-fluoro-2-(hydroxyethyl)phenyl]carboxamide

Molecular Formula:C₁₃H₁₈FNO₃

Molecular Weight:255.28500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:58.56000

Exact Mass:255.12700

LogP:3.29900

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-Butyl 4-fluoro-2-(1-hydroxyethyl)phenylcarbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(tert-butoxy)-N-[4-fluoro-2-(hydroxyethyl)phenyl]carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-Butyl 4-fluoro-2-(1-hydroxyethyl)phenylcarbamate Use and application,(tert-butoxy)-N-[4-fluoro-2-(hydroxyethyl)phenyl]carboxamide technical grade,usp/ep/jp grade.

Related News: For example, there are concerns that PFAS’ effect on the thyroid could lead to thyroid cancer, van Gerwen said. tert-butyl N-[4-fluoro-2-(1-hydroxyethyl)phenyl]carbamate manufacturer It has contracted with the Chinese manufacturer Xiamen Biotime Biotechnology to produce the tests for international distribution. According to Innova, Biotime previously submitted performance data to the agency without seeking an EUA, while the company later presented equivalent data for the same test under the Innova brand. tert-butyl N-[4-fluoro-2-(1-hydroxyethyl)phenyl]carbamate supplier Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. tert-butyl N-[4-fluoro-2-(1-hydroxyethyl)phenyl]carbamate vendor INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. tert-butyl N-[4-fluoro-2-(1-hydroxyethyl)phenyl]carbamate factory INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.